Benralizumab Inhibits Upper Airway Expression of Thymic Stromal Lymphopoietin in Severe Asthma
Summary Treatment with benralizumab significantly reduced nasal TSLP in patients with severe asthma. Nasal TSLP shows potential as a pharmacodynamic biomarker, pending validation in larger, randomized studies.
Authors
- Jalal Moolji (ORCID: https://orcid.org/0009-0009-9741-0623)
- Marc Duchesne (ORCID: https://orcid.org/0000-0003-0046-4908)
- Paige Lacy (ORCID: https://orcid.org/0000-0001-8885-6011)
- Adil Adatia (ORCID: https://orcid.org/0000-0002-7612-6529)
- Subhabrata Moitra (ORCID: https://orcid.org/0000-0002-9388-425X)
- Hazel Marriott (ORCID: https://orcid.org/0000-0002-5742-0028)
Institutions
- University of Alberta (CA)
- Ahmedabad University (IN)
Publication Details
- Journal
- Clinical & Experimental Allergy
- Published
- 2026-10-30
- DOI
- https://doi.org/10.1111/cea.70468
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00